NCT02658968 · REGISTRY CONDITION SEARCH

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1
Status at capture: COMPLETED
Registry last update: 2024-01-16

This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This is a dose escalating study to define the maximum tolerated dose (MTD) of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) in DLBCL patients who are not eligible for autologous stem cell transplant. The study will also assess safety and tolerability, pharmacokinetics, biodistribution and efficacy.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With DLTs to Determine the MTD

→

outcome · POSTED

The Best Overall Tumour Response

→

outcome · POSTED

Dosimetry

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Male or female aged ≥18 years. 2. Histologically confirmed DLBCL (WHO classification). 3. Received at least one prior line of therapy including immuno-chemotherapy. 4. In first or subsequent relapse, or refractory to the last treatment (defined as less than a complete metabolic response to the last treatment, or disease progression within 6 months from the last treatment). 5. Not suitable for, or declined/unwilling to undergo intensive therapy, including high dose chemotherapy and autologous stem cell transplantation (ASCT). 6. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (at least one objectively bi-dimensionally measurable (nodal) lesion (\>1.5 cm in its largest dimension by CT scan). 7. Negative human anti-mouse antibody (HAMA) test. 8. Life expectancy of at least 3 months. 9. Bone marrow tumour infiltration \<25% tumour cells. 10. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. 11. Normal organ and bone marrow function defined as: 1. Absolute neutrophil count ≥1.5 x 109/L 2. Platelet count ≥150 x 109/L; 3. Haemoglobin ≥9 g/dL 4. Total bilirubin ≤1.5 x upper limit of normal (ULN) (except patients with documented Gilbert's syndrome) 5. Liver enzymes: Aspartate transaminase (AST); Alanine transaminase (ALT) or Alkaline phosphatase (ALP) ≤2.5 x ULN (or ≤5.0 x ULN if liver involvement by primary disease) 6. Adequate renal function as demonstrated by a serum creatinine ≤1.5 mg/dL or a creatinine clearance \>60 mL/min 7. Normal coagulation parameters (elevated international normalized ratio (INR), prothrombin time or activated partial thromboplastin time (APTT) ≤1.3 ULN range acceptable) 12. Women of childbearing potential must: 1. Understand that the study medication may have teratogenic risk 2. Have a negative serum pregnancy test at screening and before Betalutin injection 3. Commit to continued abstinence from heterosexual intercourse (excluding periodic abstinence or the withdrawal method) or begin two acceptable methods of birth control with a Pearl-Index ≤ 1%. without interruption from 4 weeks before starting study drug, throughout study drug therapy and for 12 months after end of study drug therapy, even if she has amenorrhoea. Apart from abstinence, acceptable methods of birth control are: * Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) * Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) * Intrauterine device (IUD) * Intrauterine hormone-releasing system (IUS) * Bilateral tubal occlusion * Vasectomised partner 13. Male patients must agree to use condoms during intercourse throughout study drug therapy and the following 12 months. 14. Ability to give written, informed consent prior to any study-specific screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice. 15. Capable of understanding the protocol requirements, is willing and able to comply with the study protocol procedures, and has signed the informed consent document. 16. A negative Hepatitis B test (HBsAg and anti-HBc) and negative HIV test during screening Exclusion Criteria: 1. Prior hematopoietic allogenic stem cell transplantation. 2. Prior autologous stem cell transplantation. 3. Previous total body irradiation. 4. Prior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational agent), excluding corticosteroids within 4 weeks prior to start of study treatment (i.e. rituximab) (G-CSF or GM-CSF are permitted up to 2 weeks prior to start of study treatment.) 5. Patients who are receiving any other investigational agents. 6. Patients with known or suspected central nervous system involvement of lymphoma. 7. History of a previous treated cancer except for the following: 1. Adequately treated local basal cell or squamous cell carcinoma of the skin 2. Cervical carcinoma in situ 3. Superficial bladder cancer 4. Localized prostate cancer undergoing surveillance or surgery 5. Localised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy 6. Other adequately treated Stage 1 or 2 cancer currently in complete remission 8. Pregnant or breastfeeding women. 9. Exposure to another CD37 targeting drug. 10. Allergy to X ray contrast agents. 11. A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any excipient used in rituximab, lilotomab or Betalutin. 12. Has received a live attenuated vaccine within 30 days prior to enrolling in the study. 13. Evidence of severe or uncontrolled systemic diseases: 1. Uncontrolled infection including evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment 2. Pulmonary conditions e.g. unstable or uncompensated respiratory disease 3. Hepatic, renal neurological or metabolic conditions - which in the opinion of the investigator would compromise the protocol objectives 4. Psychiatric conditions e.g. patients unlikely to comply with the protocol, e.g. mental condition rendering the patient unable to understand the nature, scope, and possible consequences of participating in the study 5. History of erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome 6. Cardiac conditions, including: * history of acute coronary syndromes (including unstable angina) * class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; * known uncontrolled arrhythmias (except sinus arrhythmia) in the past 24 weeks.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
10 MBq/kg b.w., in escalated doses with lilotomab pre-dosing
intervention Names
Drug: Betalutin
label
Betalutin
type
EXPERIMENTAL

interventions

arm Group Labels
Betalutin
description
Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
name
Betalutin
other Names
Betalutin, lutetium (177Lu)-lilotomab satetraxetan
type
DRUG

Study design

allocation

intervention Model

SEQUENTIAL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 18
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
To determine the MTD of Betalutin that can be administered to DBLCL patients with lilotomab. The MTD was the highest dose at which less than two out of six participants experienced a dose limiting toxicity (DLT) defined as: * Haematologic toxicity: * Grade 4 neutropenia observed for greater than 7 days' duration * Grade 4 thrombocytopenia observed for greater than 7 days' duration * Grade 3 or 4 neutropenia associated with fever (≥38.5°C) of any duration * Grade 3 or 4 thrombocytopenia with bleeding * Thrombocytopenia with any requirement for more than one platelet transfusion before recovering to Grade 1 or less * Grade 4 anaemia, unexplained by underlying disease * Non-haematologic toxicity: * Grade 3 nausea/vomiting/diarrhoea lasting longer than 72 hours despite maximal care or Grade 4 * Any other Grade 3 or 4 non-haematologic toxicities * Any Grade 3 or 4 electrolyte abnormalities that do not resolve to Grade 1 or baseline within 24 hours
measure
Number of Participants With DLTs to Determine the MTD
time Frame
12 weeks

secondary Outcomes

description
Efficacy evaluations are measured by tumour response rates using CT and PET/CT imaging with responses classified as described in "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification" (Cheson, 2014). The Cheson criteria, 2014 are a combined score taking into consideration, positive or negative scored PET scan, the contrast enhanced CT images and bone marrow biopsies when available.
measure
The Best Overall Tumour Response
time Frame
3 months - 2 years
description
Dosimetry will be evaluated by the estimated absorbed radiation dose to target organs.
measure
Dosimetry
time Frame
3 weeks

Full study description

brief Summary: This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This is a dose escalating study to define the maximum tolerated dose (MTD) of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) in DLBCL patients who are not eligible for autologous stem cell transplant. The study will also assess safety and tolerability, pharmacokinetics, biodistribution and efficacy.

Source references

references

citation
Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95.
pmid
23267131
type
BACKGROUND
citation
Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013 Mar;6(1):20-7. doi: 10.2174/1874471011306010004.
pmid
23256748
type
BACKGROUND

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-1668fc8c9b446d853f00
requested nct id
NCT02658968
primary nct id
NCT02658968
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=AIDS-Related+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a8469a8cca20a75ce4fa980eaab4ff20f62c99f2a2e732f1bd42590d1d5dbe14
payload sha256
9d089ad579881bdec40580b5f5e574469226d89a4e48d20a18a921a7a7662196
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-1668fc8c9b446d853f00
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02658968
occurrences
context exact
NCT02658968
end
11
exact text
NCT02658968
start
0
offset unit
unicode_code_points
query cond
AIDS-Related Lymphoma
query disease state id
ds-aids-related-lymphoma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-aids-related-lymphoma-000.json
source file sha256
a8469a8cca20a75ce4fa980eaab4ff20f62c99f2a2e732f1bd42590d1d5dbe14
source json pointer
/studies/10/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
eb090221c5a3ee3f5585ebbe2cc70c09a07b4d0795b11a67bd9da1ba849fbb4b
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=AIDS-Related+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice